Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.

JAMA dermatology - 1 Apr 2017

Picard Alexandra, Pedeutour Florence, Peyrade Frédéric, Saudes Laurence, Duranton-Tanneur Valérie, Chamorey Emmanuel, Cardot-Leccia Nathalie, Sudaka Anne, Ettaiche Marc, Benchetrit Maxime, Poissonnet Gilles, Weinbreck Nicolas, Dadone Bérengère, Lacour Jean-Philippe, Passeron Thierry, Montaudié Henri

Abstract excerpt

IMPORTANCE: Cetuximab was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy is inconsistent and identification of predictive biomarkers for response is necessary. OBJECTIVE: To search for somatic mutations of the HRAS, KRAS, NRAS, BRAF, and EGFR genes in patients with advanced cSCC treated with cetuximab; and to investigate the efficacy and tolerance of cetuximab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to France

Share to Genes, ras

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 28259104
DOI: 10.1001/jamadermatol.2017.0270

Genes

BRAF
EGFR
HRAS
NRAS
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.PMID 28259104Read ↗

Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck DistrictSemantic proximity Read ↗

Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Semantic proximity Read ↗

Therapy of advanced squamous cell carcinoma of the skin.Semantic proximity Read ↗

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Semantic proximity Read ↗

Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.Semantic proximity Read ↗

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Semantic proximity Read ↗

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.Semantic proximity Read ↗

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Semantic proximity Read ↗

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.